BiondVax Pharmaceuticals Ltd
4:15 PM - 4:30 PM (EST), Monday, February 6, 2023 ・ Winter Garden
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) is a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. Since its inception, BiondVax has executed eight clinical trials including a seven country, 12,400 participant Phase 3 trial of its prior vaccine candidate and has built a state-of-the-art manufacturing facility for biopharmaceutical products. With highly experienced pharmaceutical industry leadership, BiondVax is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized antibody (NanoAb) pipeline generated through scientific collaboration with and exclusive licensing from the Max Planck Institute for Multidisciplinary Sciences and the University Medical Center Gottingen, both in Germany.
Ticker:
BVXV
Exchange:
Nasdaq
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Israel
Year Founded:
2003
Main Therapeutic Focus:
Platform for Therapeutics
Lead Product in Development:
Alpaca-derived inhaled nanosized antibody (NanoAb) COVID-19 therapy
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
3+
Speaker
